[Effectiveness of loratadine vs. placebo in the treatment of urticaria-angioedema syndrome in patients with food allergy].
Loratadine is a new, highly selective, non sedating, H 1-receptor antagonist, without central nervous system activity. In a randomized double-blind, crossover study, we evaluated the effects of loratadine and placebo administered once daily in 184 food intolerant patients affected by urticaria-angioedema. The difference between loratadine and placebo treatment was significant in relieving symptoms. Adverse reactions reported in the treatment were mild, in fact somnolence was reported by 3.4%, dry mouth by 2.2% of patients.
Pacor
M L
ML
Istituto di Clinica Medica, Università degli Studi di Verona.
Biasi
D
D
Girelli
D
D
Cortina
P
P
Corrocher
R
R
D000328:Adult; D000799:Angioedema / Q000150:complications* / Q000188:drug therapy; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005512:Food Hypersensitivity / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D017336:Loratadine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D012894:Sleep Stages / Q000187:drug effects; D013577:Syndrome; D014581:Urticaria / Q000150:complications* / Q000188:drug therapy; D014987:Xerostomia / Q000139:chemically induced
D010919:Placebos; D017336:Loratadine
Efficacia della loratadina versus placebo nella sindrome orticaria-angioedema in pazienti affetti da intolleranza alimentare.